NNIT Valuation
Is NNITC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NNITC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NNITC (DKK68.5) is trading below our estimate of fair value (DKK264.99)
Significantly Below Fair Value: NNITC is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NNITC?
Key metric: As NNITC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is NNITC's PS Ratio? | |
|---|---|
| PS Ratio | 0.6x |
| Sales | DKK 2.86b |
| Market Cap | DKK 1.64b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | 14.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NNITC's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.4x | ||
OPT Optima Health | 1.3x | 1.7% | UK£139.4m |
INS Instem | 3.2x | 11.4% | UK£199.6m |
IUG Intelligent Ultrasound Group | 4x | n/a | UK£39.3m |
RENX Renalytix | 12.9x | 126.2% | UK£24.0m |
NNITC NNIT | 0.6x | -14.2% | DKK 1.6b |
Price-To-Sales vs Peers: NNITC is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (5.8x).
Price to Sales Ratio vs Industry
How does NNITC's PS Ratio compare vs other companies in the European Healthcare Services Industry?
Price-To-Sales vs Industry: NNITC is good value based on its Price-To-Sales Ratio (0.6x) compared to the European Healthcare Services industry average (2.3x).
Price to Sales Ratio vs Fair Ratio
What is NNITC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NNITC's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Elevance Health
US$93.4b
Operates as a health benefits company in the United States.
0HG8
US$403.49
7D
0.4%
1Y
-15.5%
Kooth
UK£64.8m
Provides digital mental health services to children, young people, and adults in the United Kingdom.
KOO
UK£1.78
7D
7.6%
1Y
-40.4%
Enovis
US$2.7b
Operates as a medical technology company focus on developing clinically differentiated solutions worldwide.
0I1B
US$48.46
7D
9.7%
1Y
-3.3%